A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease [Estudio fase III, multicentrico, aleatorizado, doble ciego controlado con farmaco activo, de 18 meses de duracion para comparar rosiglltazona frente a gllpizida en la progresion de la aterosclerosis en sujetos con diabetes mellltus tipo 2 y enfermedad cardiovascular]

Trial Profile

A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease [Estudio fase III, multicentrico, aleatorizado, doble ciego controlado con farmaco activo, de 18 meses de duracion para comparar rosiglltazona frente a gllpizida en la progresion de la aterosclerosis en sujetos con diabetes mellltus tipo 2 y enfermedad cardiovascular]

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Rosiglitazone (Primary) ; Glipizide
  • Indications Atherosclerosis; Coronary artery disease; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Registrational
  • Acronyms APPROACH; IVUS
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Oct 2012 Planned number of patients changed from 600 to 634 as reported by European Clinical Trials Database record.
    • 01 Mar 2010 Results were published online before print in Circulation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top